查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858085

依治療類型、給藥途徑、最終用戶、藥物類別和類澱粉沉積症類型分類的類澱粉沉積症治療市場－2025-2032年全球預測

Amyloidosis Treatment Market by Treatment Type, Route Of Administration, End User, Drug Class, Amyloidosis Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，類澱粉沉積症治療市場將成長至 102.1 億美元，複合年成長率為 7.54%。

關鍵市場統計數據
基準年 2024 57億美元
預計年份：2025年 61.3億美元
預測年份 2032 102.1億美元
複合年成長率 (%) 7.54%

全面介紹近年來澱粉樣變性診斷的準確性、治療方法的拓展以及不斷發展的診療路徑，這些因素共同塑造了當今類澱粉沉積症的管理。

類澱粉沉積症已從一種罕見且常被誤診的疾病發展成為一個治療領域，其特點是診斷技術的快速改進和標靶治療的廣泛應用。近年來，生物標記檢測法、影像學技術和多模式治療方法的進步，使臨床醫生和研究人員能夠更早發現疾病並進行更準確的表現型分析。這些臨床進展為更有效地實施治療性介入和更密切地追蹤患者預後創造了機會。

同時，治療套件也在不斷擴展，涵蓋多種模式。藥物治療包括多種方法，從經典的烷化劑到新一代的TTR抑制劑和穩定劑。支持性治療在控制症狀和提高生活品質方面繼續發揮關鍵作用，尤其是在緩解疾病療法延長生存期並將重點轉向長期管理的情況下。因此，醫療服務模式也不斷調整，以平衡專科醫生主導的醫院護理、門診專科診所和居家照護的需求。

本導言透過強調診斷、治療創新和護理服務之間的相互聯繫，為更廣泛的執行摘要奠定了基礎，並強調了將臨床證據與商業計劃相結合的重要性，以抓住新興機會並應對持續存在的准入挑戰。

分子標靶治療、早期檢測和不斷發展的護理服務模式如何重新定義類澱粉沉積症的臨床和商業性重點

過去十年，由於分子標靶治療、診斷演算法的改進以及臨床實踐模式的調整，類澱粉沉積症領域的研究格局發生了顯著變化。 TTR 抑制劑和穩定器的出現重新定義了 ATTR 亞型澱粉樣變性的治療目標，並催生了直接調控潛在致病連鎖的治療方法。同時，AL類澱粉沉積症的單株抗體療法革新了標準誘導治療方案，並為對傳統療法抗藥性的患者提供了更多選擇。

診斷技術的進步，包括更靈敏的心臟影像和更精確的生物標記物，使臨床醫生能夠更早識別澱粉樣蛋白亞型，並更有把握地對患者進行風險分層。這種早期檢測促使人們更加關注能夠改變疾病進程而非僅僅緩解症狀的干涉措施，同時也凸顯了循環系統、神經科、血液病學和專科診所之間醫療協調的重要性。與治療和診斷技術的進步同步，支付方和監管機構也做出了相應調整，建立了更完善的加速核准和有條件准入項目機制，儘管在許多地區，報銷談判仍然十分複雜。

最後，醫療系統和醫療服務提供者正在調整服務模式，以滿足慢性病管理的需求。我們看到，在臨床適宜的情況下，家庭輸液和監測正在逐步整合，專科診所中心也正在興起，這些中心匯集了各方專長，能夠促進複雜療法的快速啟動。這些系統性的轉變正在從根本上重塑整個生態系統的投資重點、研發方向和商業策略。

評估2025年美國關稅改革對類澱粉沉積症治療藥物供應鏈、籌資策略和病患取得途徑的多方面影響

2025年實施的貿易政策發展和關稅調整為美國醫藥和生技藥品供應鏈的相關人員帶來了新的複雜性。特別是，影響關鍵進口產品的累積關稅措施，包括原料藥、特種化學品和某些生技藥品成品，加劇了本已採用精益庫存和準時生產模式的供應鏈的成本壓力。不斷上漲的投入成本正推高製造商的成本結構，迫使他們重新評估其分銷、採購和定價策略。

除了直接的成本影響外，關稅還可能引發採購決策和合約條款的轉變。主要企業可能會加快近岸外包或實現供應商多元化，以降低關稅波動帶來的風險；而製造外包則可能重新評估產能承諾和前置作業時間。同時，支付方和整合醫療服務網路可能會透過加強基於價值的合約談判，並要求提供更清晰的臨床獲益和長期療效的真實世界證據，來應對不斷上漲的採購成本。對於規模較小的生技公司而言，投入成本增加和供應鏈延長帶來的財務負擔可能會延緩臨床開發進程，並使商業化計畫更加複雜。

臨床醫生和患者也可能受到間接影響。零星的供應中斷和價格壓力可能會限制患者獲得特殊製劑，或導致醫療機構對某些藥物進行優先排序。為了因應這種情況，具有韌性的公司正在投資供應鏈視覺化工具、多供應商協議和策略性庫存緩衝，以確保在保持競爭力的同時，保障醫療服務的連續性。儘管貿易政策發生了更廣泛的變化，但與監管機構的溝通以及公私對話仍然是確保基本治療藥物穩定供應的關鍵工具。

將治療方式、分子類別、給藥途徑、護理環境和疾病亞型與商業性和臨床決策聯繫起來的細分市場主導洞察

對細分市場的詳細分析揭示了臨床需求與商業機會和營運風險的交匯點。依治療類型分類，可分為藥物治療、幹細胞移植及支持性治療。藥物治療又可分為烷化劑、免疫調節劑、單株抗體、蛋白酶體抑制劑、TTR 沉默劑和 TTR 穩定劑；例如，Melphalan（烷化劑） 、來Lenalidomide（免疫調節劑）、Daratumumab妥尤單抗（單株抗體）、Bortezomib、Carfilzomib、Ixazomib（RTT）、米佐酶蛋白和可拉米佐素（RTTRTT）。穩定劑）。依給藥途徑分類，可分為靜脈注射、口服和皮下注射，每種途徑在物流、遵從性和治療部位方面均有所不同。

從最終用戶的角度來看，護理服務透過居家照護、醫院和專科診所提供，每個管道都會影響產品設計、病患支援需求和報銷途徑。在藥物類別中，重疊的藥理學分類和分子機制揭示了治療替代和聯合策略在臨床上可能合理的領域。最後，類澱粉沉積症的類型——AA型、AL型、遺傳性ATTR型和野生型ATTR型——具有顯著不同的臨床表現和進展，這會影響移植資格、緩解疾病療法的選擇以及支持治療的重點。

綜上所述，此細分矩陣支援有針對性的產品開發、精準的商業性策略、差異化的患者支援模式，並透過明確與監管審查員和支付方產生共鳴的終點和亞組分層，幫助進行臨床試驗設計。

不同區域的細微差別會影響全球類澱粉沉積症治療全部區域的診斷、報銷途徑、供應鏈韌性和實施時間表。

區域動態持續影響醫療服務取得、投資和臨床實踐，因此需要採取不同的策略。在美洲，集中的研究基礎和歷來良好的創新資助環境支持新型療法和診斷技術的快速應用，但公立和私立醫療體系中不同的支付方政策導致患者就醫和報銷時間存在差異。相較之下，歐洲、中東和非洲地區的情況則更為複雜，單一支付方體系使得醫療服務取得途徑更加標準化，但部分市場面臨的基礎設施限制也減緩了高成本治療方法的普及。

亞太市場因其生物製藥生產的快速擴張和多樣化的監管方式而極具吸引力。該地區多個國家正在建立本地生產能力和法律規範，旨在吸引臨床研發活動並減少對外部供應鏈的依賴。各地區在診斷能力、專家資源和本地治療指南方面存在差異，這會影響新治療方法從核准到常規應用的速度。在資源匱乏的地區，支持性治療和症狀管理通常是首要任務；而在資源豐富的地區，則越來越重視緩解疾病和綜合護理模式。

因此，策略性參與企業需要根據當地情況調整其商業化、醫療事務和供應策略，包括根據當地證據要求調整價值證明材料，在診斷素養較低的地方投資臨床醫生教育，以及建立製造或採購夥伴關係，以加快患者用藥時間，同時減輕關稅和物流負擔。

大型製藥公司的規模、生物技術創新、診斷夥伴關係以及生產策略之間的相互作用決定了其在類澱粉沉積症領域的競爭地位。

類澱粉沉積症領域的競爭格局由大型製藥企業、專業生物技術公司、受託製造和診斷公司組成，它們共同塑造了該領域的創新和競爭格局。擁有完善商業性基礎設施的成熟製藥公司在擴大核准治療方法的覆蓋範圍和協商複雜的醫保報銷協議方面發揮著關鍵作用，而靈活的生物技術公司則往往在下一代抑製劑、穩定劑和靶向生技藥品的早期創新方面發揮著主導作用。

戰略夥伴關係和許可協議已成為加速臨床開發和產品上市的關鍵。治療藥物研發商與診斷服務提供者之間的合作日益重要，以確保準確識別患者，並支持支撐價值導向協議的伴隨診斷策略。受託製造廠商和區域製造商也發揮關鍵作用，它們能夠幫助降低關稅影響，並建立本地化的供應鏈，從而縮短關鍵治療方法的前置作業時間。

投資者和潛在合作夥伴應密切關注產品研發管線進展、監管里程碑以及能夠凸顯產品臨床效用和實際應用價值的證據產生策略。那些在核准後積極收集證據、增加對患者支持服務的投入並積極與支付方和臨床醫生網路互動的公司，更有可能將臨床療效轉化為在各種醫療環境中持續應用。

製造商、支付者和醫療保健提供者可採取的策略重點，以改善澱粉樣變性治療藥物的可及性，確保供應穩定性，並展現其持續的臨床價值。

產業領導者應採取多管齊下的策略，在不斷變化的政策和供應挑戰下，充分發揮臨床價值並維持藥物可及性。他們應優先投資於診斷基礎設施和臨床醫生培訓，以促進早期發現和適當的亞型分類，並提高疾病修正治療的臨床效用。同時，他們應制定循證醫學方案，將隨機數據與真實世界證據相結合，以支持與支付方進行深入的價值評估討論，並降低在不同報銷環境下納入醫保目錄的風險。

透過供應商多角化、選擇性近岸外包以及關鍵投入品的策略性庫存緩衝，增強供應鏈韌性。與供應商和物流夥伴協商靈活的合約條款，以應對關稅波動並確保醫療服務的連續性。產品開發應與目標患者群體的給藥途徑偏好相符，認知到口服和皮下製劑為居家照護提供了更多機會，而靜脈注射方案通常需要醫院和診所的資源。

最後，要與包括診斷機構、專科診所和患者權益組織在內的整個生態系統建立夥伴關係，以創建全面的護理路徑，從而提高患者依從性、監測治療效果並支持長期疾病管理。在可行的情況下採用基於結果的契約，並投資於能夠實現遠端監測和患者參與的數位化工具，將有助於強化治療價值的實際應用案例，並使報銷談判更加可預測。

採用穩健的混合方法研究途徑，結合臨床專家見解、公開監管記錄和系統性文獻綜述，以確保得出基於證據的結論。

本分析透過整合一手和二手研究，平衡了臨床、商業和營運方面的動態因素。一手研究結合了對關鍵意見領袖（包括血液科醫生、循環系統、神經科、專科診所主任和採購負責人）的結構化訪談，以及與行業高管的對話，以闡明產品線發展和研發策略的背景。二手研究是對同行評審的臨床文獻、監管核准和附加檔更新、臨床試驗註冊資訊以及上市公司披露資訊進行系統性回顧，並輔以對診斷指南更新和支付方政策公告的研究。

數據三角驗證確保了臨床研究結果與觀察到的商業性行為和供應鏈實際情況相符。透過專家訪談獲得的定性見解與已發表的試驗結果和監管文件進行交叉檢驗，以減少偏差並完善解讀。分析技術包括對定性輸入進行主題綜合分析，以及對區域和細分市場差異進行比較趨勢分析。調查方法優先考慮假設的透明度，並明確排除對市場規模的推測或預測，重點關注可操作的資訊和基於證據的建議。

總結了將診斷進步、治療方法多樣化和技術創新轉化為更廣泛的患者影響所需的策略行動結論。

總之，類澱粉沉積症領域正進入一個診斷技術日益精進、治療方法日益多樣化的新階段，二者相輔相成，為改善患者預後和實現策略性商業性成長創造了切實機會。臨床醫生如今能夠獲得更多種類的緩解疾病藥物和支持策略，醫療系統也正在調整服務模式以適應慢性病管理路徑。貿易政策的變化和供應鏈壓力凸顯了製定穩健籌資策略的必要性，而區域差異則要求制定量身定做的市場准入和循證醫學方案。

對於整個生態系統中的相關人員，將臨床創新與切實可行的准入機制和營運準備相結合，是未來的發展方向。透過投資診斷、建立策略夥伴關係以及收集有意義的真實世界證據，各機構可以縮小臨床潛力與更廣泛的患者獲益之間的差距。本文提出的建議為應對類澱粉沉積症治療領域不斷變化的治療、監管和商業環境提供了藍圖。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • RNA干擾療法的快速應用重塑了遺傳性轉甲狀腺素類澱粉沉積症治療的模式。
  • 擴大基因篩檢項目，以促進對類澱粉沉積症患者的早期診斷和介入。
  • 整合先進的澱粉樣成像技術，以改善治療監測和患者分層
  • 生技公司與大型製藥公司結成策略聯盟，加速新型類澱粉沉積症藥物的研發
  • 報銷方面的挑戰和支付方政策的轉變影響著病患獲得高成本類澱粉沉積症治療的機會。
  • 針對錯誤折疊蛋白聚集體的單株抗體類澱粉沉積症在系統性類澱粉沉積症治療的應用
  • 增加真實世界證據研究，以便更好地了解類澱粉沉積症治療的長期療效和安全性

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療類型類澱粉沉積症治療市場

  • 藥物治療
    • 烷化劑
      • Melphalan
    • 免疫調節藥物
      • Lenalidomide
    • 單株抗體
      • Daratumumab
    • 蛋白酶體抑制劑
      • Bortezomib
      • Carfilzomib
      • Ixazomib
    • TTR消音器
      • 伊諾塔岑
      • 派蒂西蘭
    • TTR穩定器
      • 阿科拉米迪斯
      • 塔法米迪斯
  • 幹細胞移植
  • 支持性護理

第9章 依給藥途徑分類的類澱粉沉積症治療市場

  • 靜脈注射
  • 口服
  • 皮下

第10章 依最終用戶分類的類澱粉沉積症治療市場

  • 居家照護
  • 醫院
  • 專科診所

第11章 依藥物類別分類的類澱粉沉積症治療市場

  • 烷化劑
    • Melphalan
  • 免疫調節藥物
    • Lenalidomide
  • 單株抗體
    • Daratumumab
  • 蛋白酶體抑制劑
    • Bortezomib
    • Carfilzomib
    • Ixazomib
  • TTR消音器
    • 伊諾塔岑
    • 派蒂西蘭
  • TTR穩定器
    • 阿科拉米迪斯
    • 塔法米迪斯

第12章 依類澱粉沉積症類型分類的類澱粉沉積症治療市場

  • AA
  • AL
  • 遺傳性ATTR
  • 野生型 ATTR

第13章 各地區澱粉樣類澱粉沉積症治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章類澱粉沉積症治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國類澱粉沉積症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Johnson & Johnson（Janssen Biotech, Inc.）
    • Ionis Pharmaceuticals, Inc.
    • BridgeBio Pharma, Inc.
    • Prothena Corporation plc
Product Code: MRR-C002B1C996F0

The Amyloidosis Treatment Market is projected to grow by USD 10.21 billion at a CAGR of 7.54% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.70 billion
Estimated Year [2025] USD 6.13 billion
Forecast Year [2032] USD 10.21 billion
CAGR (%) 7.54%

Comprehensive orientation to recent diagnostic precision, therapeutic expansion, and evolving care pathways shaping amyloidosis management today

Amyloidosis has evolved from a rare, often misdiagnosed condition into a therapeutic area marked by rapid diagnostic refinement and a proliferation of targeted treatments. In recent years, clinicians and researchers have benefited from improved biomarker assays, imaging modalities, and multidisciplinary care pathways that together enable earlier detection and more precise phenotyping. These clinical advances create opportunities for therapeutic interventions to be deployed more effectively and for patient outcomes to be tracked with greater granularity.

Concurrently, the treatment toolkit has expanded across multiple modalities. Pharmacological treatments encompass a range of approaches from classic alkylating agents to next-generation TTR silencers and stabilizers, while autologous stem cell transplantation remains a curative-intent option for eligible patients. Supportive therapies continue to play a pivotal role in symptom control and quality-of-life enhancement, particularly as disease-modifying agents extend survival and shift focus toward long-term management. As a result, care delivery models are adapting to balance specialist-driven hospital care, outpatient specialty clinics, and increasing home-based services.

This introduction frames the broader executive summary by emphasizing the interplay between diagnostics, therapeutic innovation, and care delivery. It sets the stage for deeper analysis of market dynamics, regulatory pathways, and stakeholder strategies that follow, while underscoring the importance of integrating clinical evidence with commercial planning to capitalize on emerging opportunities and to address persistent access challenges.

How targeted molecular therapies, earlier detection, and evolving care delivery models are collectively redefining clinical and commercial priorities in amyloidosis

Over the past decade, the amyloidosis landscape has experienced transformative shifts driven by targeted molecular therapies, improved diagnostic algorithms, and a recalibration of clinical practice patterns. The arrival of TTR silencers and stabilizers has reframed treatment goals for ATTR subtypes, bringing therapies that directly modulate the underlying pathogenic cascade. At the same time, monoclonal antibody approaches for AL amyloidosis have changed standard induction regimens and expanded options for patients who were previously refractory to conventional regimens.

Diagnostic progress, including more sensitive cardiac imaging and refined biomarkers, has enabled clinicians to identify amyloid subtypes earlier and to stratify patients by risk with greater confidence. This earlier detection translates into heightened demand for interventions that can alter disease trajectory rather than simply palliate symptoms, and it increases the importance of care coordination across cardiology, neurology, hematology, and specialized clinics. Parallel to therapeutic and diagnostic advances, payer and regulatory environments have adapted by creating more robust pathways for accelerated approvals and conditional access programs, although reimbursement negotiations remain complex in many jurisdictions.

Finally, health systems and providers are adapting delivery models to accommodate chronic management needs. There is a visible shift toward integrating home-based infusion and monitoring where clinically appropriate, and toward specialty clinic hubs that concentrate expertise and facilitate rapid initiation of complex therapies. These systemic shifts are collectively reshaping investment priorities, R&D focus, and commercial strategies across the ecosystem.

Assessing the multifaceted effects of 2025 United States tariff changes on pharmaceutical supply chains, procurement strategies, and patient access in amyloidosis care

Trade policy developments and tariff adjustments instituted in 2025 have introduced another layer of complexity for stakeholders operating in the United States pharmaceutical and biologics supply chains. Cumulative tariff measures, particularly those affecting key import categories such as active pharmaceutical ingredients, specialty chemicals, and certain finished biologics components, have increased the cost pressure on supply chains that are already operating with lean inventories and just-in-time manufacturing approaches. These elevated input costs exert upward pressure on manufacturers' cost structures and force reassessment of distribution, procurement, and pricing strategies.

Beyond direct cost impacts, tariffs can induce shifts in sourcing decisions and contractual terms. Companies may accelerate nearshoring or diversify supplier bases to mitigate exposure to tariff volatility, while contract manufacturers reassess capacity commitments and lead times. In tandem, payers and integrated delivery networks may respond to rising acquisition costs by intensifying value-based contracting discussions, demanding clearer real-world evidence of clinical benefit and long-term outcomes. For smaller biotech firms, the financial strain of increased input costs and elongated supply chains can slow clinical development timelines and complicate commercialization plans.

Clinicians and patients can also experience indirect effects: sporadic supply disruptions or pricing pressures may constrain access to specialized formulations or result in prioritization schemes by providers. In response, resilient companies are investing in supply chain visibility tools, multi-sourcing agreements, and strategic inventory buffers to preserve continuity of care while maintaining competitive positioning. Regulatory engagement and public-private dialogue remain important levers to ensure essential therapies maintain stable availability despite broader trade policy shifts.

Segment-driven insights that link therapeutic modality, molecular class, administration route, care setting, and disease subtype to commercial and clinical decision-making

A granular view of segmentation illuminates where clinical needs intersect with commercial opportunity and operational risk. Based on treatment type, the therapeutic landscape encompasses pharmacological treatment, stem cell transplantation, and supportive therapy, with pharmacological options further categorized into alkylating agents, immunomodulators, monoclonal antibodies, proteasome inhibitors, TTR silencers, and TTR stabilizers; examples within these classes include melphalan among alkylating agents, lenalidomide among immunomodulators, daratumumab within monoclonal antibodies, bortezomib, carfilzomib and ixazomib among proteasome inhibitors, and inotersen and patisiran representing TTR silencers while acoramidis and tafamidis exemplify TTR stabilizers. Based on route of administration, therapies span intravenous, oral, and subcutaneous delivery, each of which imposes distinct logistical, adherence, and site-of-care implications for deployment.

Examining end users, care is delivered across home care settings, hospitals, and specialty clinics, and each channel shapes product design, patient support needs, and reimbursement pathways. Based on drug class segmentation, the overlap between pharmacological taxonomy and molecular mechanism highlights where therapeutic substitution or combination strategies are clinically plausible. Finally, by amyloidosis type including AA, AL, hereditary ATTR, and wild-type ATTR, clinical presentation and progression differ markedly, which in turn influence the suitability of transplantation, the selection of disease-modifying agents, and the emphasis on supportive care.

Taken together, this segmentation matrix supports targeted product development, precision commercial approaches, and differentiated patient support models. It also informs clinical trial design by clarifying endpoints and subgroup stratification that resonate with regulatory reviewers and payer assessments.

Nuanced regional considerations affecting diagnostics, reimbursement pathways, supply chain resilience, and adoption timelines across global amyloidosis care geographies

Regional dynamics continue to shape access, investment, and clinical practice in ways that require tailored strategies. In the Americas, concentrated centers of excellence and a historically aggressive innovation funding environment support rapid adoption of novel therapeutics and diagnostic technologies, but divergent payer policies across public and private systems create variability in patient access and reimbursement timelines. In contrast, the Europe, Middle East & Africa region presents a heterogeneous mosaic where single-payer jurisdictions may enable more standardized adoption pathways while other markets face infrastructural constraints that delay diffusion of high-cost therapies.

Asia-Pacific markets exhibit a mix of rapid biopharmaceutical manufacturing expansion and diverse regulatory approaches; several countries within the region are building local production capabilities and regulatory frameworks that aim to both attract clinical development activity and lower dependence on external supply chains. Across regions, variations in diagnostic capacity, specialist availability, and local treatment guidelines influence how rapidly new modalities move from approval to routine care. In low-resource settings, supportive care and symptom management often remain the immediate priorities, while high-resource systems increasingly emphasize long-term disease modification and integrated care models.

Strategic entrants must therefore align commercialization, medical affairs, and supply strategies to regional nuances. This includes adapting value demonstration dossiers to local evidence requirements, investing in clinician education where diagnostic literacy remains nascent, and establishing manufacturing or sourcing partnerships to reduce tariff and logistics exposure while accelerating time to patient.

How the interplay between big pharma scale, biotech innovation, diagnostics partnerships, and manufacturing strategies is determining competitive positioning in amyloidosis

Competitive activity across the amyloidosis space reflects a mix of large pharmaceutical companies, specialized biotech innovators, contract manufacturing organizations, and diagnostics firms that together shape the innovation and access landscape. Established pharmaceutical companies with broad commercial infrastructures play a pivotal role in scaling approved therapies and negotiating complex reimbursement arrangements, while nimble biotech firms tend to drive early-stage innovation in next-generation silencers, stabilizers, and targeted biologics.

Strategic partnerships and licensing agreements have become central to accelerating clinical development and market entry. Collaborations between therapy developers and diagnostics providers are increasingly important to ensure accurate patient identification and to support companion diagnostic strategies that underpin value-based contracting. Contract manufacturing organizations and regional producers also play a critical role by offering capacity to mitigate tariff exposure and to enable localized supply chains that reduce lead times for critical therapies.

Investors and potential partners should monitor pipeline progression, regulatory milestones, and evidence-generation strategies that differentiate products in terms of clinical benefit and real-world applicability. Companies that demonstrate robust post-approval evidence collection, invest in patient support services, and proactively engage payers and clinician networks are better positioned to translate clinical promise into sustainable adoption across diverse care settings.

Actionable strategic priorities for manufacturers, payers, and providers to enhance access, ensure supply resilience, and demonstrate sustained clinical value in amyloidosis

Industry leaders should adopt a multi-pronged approach to capture clinical value and to sustain access amidst evolving policy and supply challenges. Prioritize investments in diagnostic infrastructure and clinician education to drive earlier detection and appropriate subtype assignment, thereby increasing the clinical utility of disease-modifying therapies. Concurrently, design evidence-generation plans that combine randomized data with pragmatic real-world evidence to support robust value conversations with payers and to de-risk formulary inclusion across different reimbursement environments.

Reinforce supply chain resilience through supplier diversification, selective nearshoring, and strategic inventory buffers for critical inputs. Negotiate flexible contractual terms with suppliers and logistics partners to accommodate tariff volatility and to preserve continuity of care. Align product development with route-of-administration preferences for targeted patient cohorts, recognizing that oral and subcutaneous formulations can expand home-based care opportunities while intravenous regimens often require hospital or clinic resources.

Finally, cultivate partnerships across the ecosystem-including diagnostics providers, specialty clinics, and patient advocacy groups-to build comprehensive care pathways that improve adherence, monitor outcomes, and support long-term disease management. Embrace outcome-based contracting where feasible, and invest in digital tools that enable remote monitoring and patient engagement, thereby strengthening the real-world case for therapeutic value and enabling more predictable reimbursement conversations.

Robust mixed-methods research approach combining clinical expert insights, public regulatory records, and systematic literature review to ensure evidence-driven conclusions

This analysis synthesizes primary and secondary research methods to deliver a balanced view of clinical, commercial, and operational dynamics. Primary research comprised structured interviews with key opinion leaders including hematologists, cardiologists, neurologists, specialty clinic directors, and procurement executives, combined with dialogues with industry executives to contextualize pipeline developments and commercialization strategies. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory approvals and label updates, clinical trial registries, and public company disclosures, augmented by an examination of diagnostic guideline updates and payer policy announcements.

Data triangulation ensured that clinical findings align with observed commercial behaviors and supply chain realities. Qualitative insights from expert interviews were cross-validated with published trial outcomes and regulatory documentation to mitigate bias and to refine interpretations. Analytical techniques included thematic synthesis for qualitative inputs and comparative trend mapping to highlight regional and segment-level differences. The methodology prioritized transparency in assumptions and explicitly excluded speculative market sizing or forecasting to maintain focus on actionable intelligence and evidence-based recommendations.

Concluding synthesis of diagnostic advances, therapeutic diversification, and strategic actions required to translate innovation into broader patient impact

In conclusion, the amyloidosis landscape is entering a phase where diagnostic sophistication and therapeutic diversity converge to create tangible opportunities for improved patient outcomes and strategic commercial growth. Clinicians now have access to a wider array of disease-modifying agents and supportive strategies, and health systems are recalibrating care delivery to accommodate chronic management pathways. Trade policy shifts and supply chain pressures underscore the need for resilient sourcing strategies, while regional heterogeneity demands tailored market entry and evidence-generation plans.

For stakeholders across the ecosystem, the path forward involves aligning clinical innovation with pragmatic access mechanisms and operational preparedness. By investing in diagnostics, forging strategic partnerships, and collecting meaningful real-world evidence, organizations can bridge the gap between clinical potential and widespread patient benefit. The recommendations contained herein provide a roadmap for navigating the evolving therapeutic, regulatory, and commercial environment surrounding amyloidosis treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of RNA interference therapies reshaping hereditary transthyretin amyloidosis treatment landscape
  • 5.2. Expansion of genetic screening programs driving earlier diagnosis and intervention for amyloidosis patients
  • 5.3. Integration of advanced amyloid imaging techniques improving treatment monitoring and patient stratification
  • 5.4. Strategic alliances between biotech firms and large pharmaceutical companies accelerating novel amyloidosis drug development
  • 5.5. Reimbursement challenges and payer policy variations impacting patient access to high-cost amyloidosis treatments
  • 5.6. Emergence of monoclonal antibody therapies targeting misfolded protein aggregates in systemic amyloidosis treatment
  • 5.7. Increasing real-world evidence studies enhancing understanding of long-term efficacy and safety of amyloidosis therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amyloidosis Treatment Market, by Treatment Type

  • 8.1. Pharmacological Treatment
    • 8.1.1. Alkylating Agents
      • 8.1.1.1. Melphalan
    • 8.1.2. Immunomodulators
      • 8.1.2.1. Lenalidomide
    • 8.1.3. Monoclonal Antibodies
      • 8.1.3.1. Daratumumab
    • 8.1.4. Proteasome Inhibitors
      • 8.1.4.1. Bortezomib
      • 8.1.4.2. Carfilzomib
      • 8.1.4.3. Ixazomib
    • 8.1.5. TTR Silencers
      • 8.1.5.1. Inotersen
      • 8.1.5.2. Patisiran
    • 8.1.6. TTR Stabilizers
      • 8.1.6.1. Acoramidis
      • 8.1.6.2. Tafamidis
  • 8.2. Stem Cell Transplantation
  • 8.3. Supportive Therapy

9. Amyloidosis Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Amyloidosis Treatment Market, by End User

  • 10.1. Home Care
  • 10.2. Hospital
  • 10.3. Specialty Clinic

11. Amyloidosis Treatment Market, by Drug Class

  • 11.1. Alkylating Agents
    • 11.1.1. Melphalan
  • 11.2. Immunomodulators
    • 11.2.1. Lenalidomide
  • 11.3. Monoclonal Antibodies
    • 11.3.1. Daratumumab
  • 11.4. Proteasome Inhibitors
    • 11.4.1. Bortezomib
    • 11.4.2. Carfilzomib
    • 11.4.3. Ixazomib
  • 11.5. TTR Silencers
    • 11.5.1. Inotersen
    • 11.5.2. Patisiran
  • 11.6. TTR Stabilizers
    • 11.6.1. Acoramidis
    • 11.6.2. Tafamidis

12. Amyloidosis Treatment Market, by Amyloidosis Type

  • 12.1. AA
  • 12.2. AL
  • 12.3. Hereditary ATTR
  • 12.4. Wild-Type ATTR

13. Amyloidosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Amyloidosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Amyloidosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Alnylam Pharmaceuticals, Inc.
    • 16.3.3. Johnson & Johnson (Janssen Biotech, Inc.)
    • 16.3.4. Ionis Pharmaceuticals, Inc.
    • 16.3.5. BridgeBio Pharma, Inc.
    • 16.3.6. Prothena Corporation plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLI